欢迎访问文传商讯!

全部新闻

Boehringer Ingelheim and Lilly’s CAROLINA cardiovascular outcome trial for Trajenta meets primary endpoint of non-inferiority compared to glimepiride

发布时间:2019-02-15 09:29


Trajenta demonstrates no increased cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk
With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile of Trajenta in a broad range of adults with type 2 diabetes

INGELHEIM, Germany & INDIANAPOLIS -- (BUSINESS WIRE) --

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority of Trajenta® (linagliptin) vs glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).1,2

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190214005409/en/

CAROLINA® is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor.1,2 The trial evaluated the cardiovascular safety of linagliptin (5 mg once daily) compared to the sulphonylurea glimepiride, on top of standard of care in 6,033 adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease.1,2 The trial assessed linagliptin safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than 6 years.1,2 The overall safety profile of linagliptin in CAROLINA® was consistent with previous data and no new safety signals were observed.3

People who have type 2 diabetes are at an increased risk of cardiovascular disease and, despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for this population.4 Together with CARMELINA®, the placebo-controlled cardiovascular outcome trial, which demonstrated long-term cardiovascular safety in adults with type 2 diabetes at high risk for heart and kidney disease,5 CAROLINA® confirms linagliptin’s long-term overall safety profile in a broad range of adults with type 2 diabetes.

“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine, Boehringer Ingelheim. “When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINA® expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”

“These data provide further confidence in the well-established safety and tolerability profile of linagliptin for the treatment of adults with type 2 diabetes,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “Linagliptin is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”

The full results of CAROLINA® will be presented on 10 June at the American Diabetes Association’s 79th Scientific Sessions in San Francisco, United States.

About CAROLINA®
CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) is a multi-national, randomised, double-blind, active-controlled clinical trial that involved 6,033 adults with type 2 diabetes from 43 countries at more than 600 sites observed for a median duration of more than 6 years.1,2 The trial included adults with early type 2 diabetes: adults with a median disease duration of 6.2 years, who either received no treatment at all, or received 1-2 glucose lowering agents (e.g. metformin).2 It was designed to assess the effect of Trajenta® (linagliptin) (5 mg once daily) compared to the sulphonylurea glimepiride (both added to stable background glucose-lowering medication and cardiovascular standard of care) on cardiovascular safety in adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease.1,2 These people reflect patients that doctors typically see in their daily clinical practice.6

CAROLINA® was led by an academic trial steering committee and Boehringer Ingelheim and Eli Lilly and Company. CAROLINA® is the first DPP-4 inhibitor, active-comparator cardiovascular outcome trial.

About Trajenta® (linagliptin)
Trajenta® is a one dose, once daily DPP-4 inhibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for adults with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.3 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.7,8,9,10

About our cardiovascular outcome trials
Cardiovascular outcome trials are highly relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes. Worldwide, most people with type 2 diabetes die of a cardiovascular event.4 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with type 2 diabetes and established cardiovascular disease, on top of standard of care.11,12,13,14,15 As a result, empagliflozin was the first oral type 2 diabetes medicine to have either a cardiovascular indication or data on the reduction of the risk of cardiovascular death included in the label in many countries.11,12

CAROLINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor, linagliptin.1,2 CAROLINA® and the CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk trial (CARMELINA®)5,16 provide one of the most comprehensive datasets on the long-term safety of a DPP-4-inhibitor.

CARMELINA® is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.5,14 CARMELINA® studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.5,14 The trial met its primary endpoint,17 with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.5 CARMELINA® also included a key secondary composite endpoint,18 showing a similar kidney safety profile compared to placebo.5 The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.3,5 CARMELINA® also showed a similar rate of hospitalisation for heart failure for linagliptin compared to placebo.5

To learn ore about CARMELINA®, please visit: https://www.carmelinatrial.com/

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/CAROLINA-top-line

View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005409/en/

CONTACT:

Tetsu Owari
Media & PR
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 184867

Stephan Thalen
Global Business Communications
Lilly Diabetes
Email: stephan.thalen@lilly.com
Phone: +1 317 903 5640

金联创 xinhua08 cacs takungpao China.com 和讯 财讯 C114.net 看商界 畅享网 中国能源网 证券之星 金融界 中金在线 天和网 中国金融网 中汽传媒 国际财经日报 中国环保网 今日亚洲新闻网 百歌新闻专线 亚洲商机 新华网能源频道 IT资讯网 中国智能卡论坛 广西物流网 品牌世家 汽车点评网 中国电子标签网 360教育在线 21世纪保险网 中国能源投资网 中国电子商业联盟 中国汽车咨询中心网 煤炭供应链 美国证券网 百奥知 CTI论坛 中国测控网 北极星电力网 能源财经网 福建之窗 智库在线 eeworld 电脑商情在线 中国电池网 赢商网 湖南信息港 赢在中国网 比邻星环保网 中国制造业门户 中国涂料在线 渝网 - 了解重庆第一站,重庆城市生活门户网站 中国云计算第一门户网站—中云网 投资界 i美股 天和财富网 太阳能信息网 爱中国能源网 世纪新能源网 中国新能源网 PVMate.com 环球外汇 橡胶网-hc360慧聪网 百年企业在线 IT168 米内 汽车工业网 第一车市汽车网 股市资讯 中国西部网 中原汽配网 科技在线 煤炭网 51招生网 教育人生 驴皮网 物流北京 51电池搜索网 大众医学 岭南医药网 5联网 股城网 BIT CNELC XXTLW 外汇通 供应链中国网 中国粘合剂网 中国储能网 家具迷 家居装修网 中華检测网 中国食品招商网 华东化工网 新疆第一汽车网 中国汽车用品交易网 大娱网 中国汽配网 山东化工网 960化工网 妈咪爱 塑胶五金网 慧聪电子网 迈点酒店网 火爆网 emcsino eetrend 绿色节能网 赤浪绿色新能源网 中国商业网 生物无忧 全球医疗器械网 贷商网 手机在线 汽车轻量化在线 中国汽车材料网 科易网 中国电子顶级开发网 中国POS机网 乐康家居 必修 国易网